Know Cancer

forgot password

A Multi-centre Randomised Controlled Double-blinded Trial of BCG and Interferon Alpha in High Risk Superficial Bladder Cancer

Phase 2/Phase 3
18 Years
Not Enrolling
Carcinoma of Urinary Bladder, Superficial

Thank you

Trial Information

A Multi-centre Randomised Controlled Double-blinded Trial of BCG and Interferon Alpha in High Risk Superficial Bladder Cancer

140 eligible patients with high risk superifical bladder cancer would be randomised to
receive standard dose BCG, low dose BCG or the combination of low dose BCG and interferon
alpha in a schedule of "6+3" weekly intravesical instillations. Patients would be closely
monitored with cystoscopy and urine cytology and intravenous urograms when indicated.
Pre-and post-instillation urine samples would be collected for cytokine analysis.

Inclusion Criteria:

(1) Patients must have completely resected, histologically?proven urothelial carcinoma of
the urinary bladder, stage Ta or Tl 1 ? 16 weeks prior to registration, and/or
carcinoma-in-situ on bladder biopsy. Central pathology review was mandatory. (2) Patients
with Stage Ta urothelial carcinoma must be judged to be at increased risk of tumor
recurrence by virtue of any one of the following: (a) Tumor recurrence during the 56 weeks
prior to registration, (b) Two or more initial tumors within 28 weeks, (c) Grade III
urothelial carcinoma during the 16 weeks prior to registration, (d) Dysplasia or
carcinoma-in-situ on random biopsy or (e) Positive urinary cytology post tumor resection.
"Suspicious" or "suggestive" cytology is insufficient for this criterion. (3) Patients who
have received prior intravesical therapy other than BCG were eligible provided they had
not undergone a course of any other intravesical agent within two months prior to entry.
(4) There was no age restriction; however, all patients registered had to be willing to be
available for 5?year follow up and to have a life expectancy of at least two years. (5)
Patients had a Karnofsky score >50. (6) Women of child?bearing age were using effective
contraceptive methods. (7) Patients agreed not to take vitamin supplements (except for
those prescribed in the study) for the duration of the trial. (8) Pretreatment laboratory
tests and radiological examinations must have been obtained during the 16 weeks prior to
patient registration. (9) All patients had to be informed of the investigational nature of
this study, and had to sign a written informed consent in accordance with institutional

Exclusion Criteria:

- (1) Patients with medical illness or mental status, which would preclude cooperation
with the study. (2) Patients who were immunodeficient, or had received
immunosuppressive radiation therapy or chemotherapy. (3) Patients with urothelial
carcinoma of stage T2 or higher. (4) Patients who had evidence of urothelial
carcinoma of the upper urinary tract at the time of recruitment. (5) Patients who had
received radiation therapy for bladder cancer within one year prior to registration.
(6) Patients who had been previously treated with intravesical BCG. (7) Patients with
active tuberculosis.

Type of Study:


Study Design:

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment

Outcome Measure:

local toxicity

Principal Investigator

Kesavan Esuvaranathan, FRCSEd MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

National University, Singapore


Singapore: Health Sciences Authority

Study ID:




Start Date:

October 1995

Completion Date:

June 2005

Related Keywords:

  • Carcinoma of Urinary Bladder, Superficial
  • bladder cancer
  • BCG
  • interferon alpha
  • Urinary Bladder Neoplasms
  • Carcinoma